COMMUNIQUÉS West-GlobeNewswire

CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
14/09/2026
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, [...]
Quiet Communities and Science for Georgia Release First-of-its-Kind Study on the Impacts of Data Center and Cryptomining Noise
14/09/2026
New national survey documents widespread reports of persistent noise and disrupted quality of life as AI data centers and cryptomines rapidly expand across the United States LINCOLN, Mass. and ATLANTA, Sept. 14, 2026 ( [...]
KFSH Riyadh Records Zero High-Risk Findings Across Nearly 1,800 Measures in JCI Reaccreditation
14/09/2026
RIYADH, Saudi Arabia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has secured reaccreditation as an Academic Medical Center from Joint Commission International [...]
GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
14/09/2026
GENFIT's acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needs The investigation in Phase 2 is supported by a [...]
GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF
14/09/2026
L’acquisition par GENFIT du nangibotide, un candidat-médicament au profil différencié en phase avancée de développement clinique, renforce le portefeuille de thérapies innovantes de la Société adressant d’importants [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026
14/09/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 7th September to 11th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2026
14/09/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 7 septembre au 11 septembre 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
Paralyzed Marine Veteran Stands and Walks at Enjoy Illinois 300 as Patriot Mobile Puts SoldierStrong on Ty Dillon's No. 10
14/09/2026
STAMFORD, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- SoldierStrong, the national nonprofit committed to delivering revolutionary medical technologies to America's veterans, brought its mission to the NASCAR Cup Series [...]
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
14/09/2026
Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
Wellthy Acquires Cleo as Two Leaders Come Together to Create the Singular Platform for Family Care
14/09/2026
Wellthy's acquisition of Cleo brings together two leaders in family care, expanding support for employers, health plans, and families. NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Wellthy today announced its acquisition [...]
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
14/09/2026
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS [...]
New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System
14/09/2026
MILPITAS, Calif. and TOKYO , Sept. 14, 2026 (GLOBE NEWSWIRE) -- New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System MILPITAS, Calif. and TOKYO [...]
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
14/09/2026
Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first- [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on Oct 7
14/09/2026
September 14, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
14/09/2026
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil [...]
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
14/09/2026
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“ [...]
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
14/09/2026
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. ( [...]
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
14/09/2026
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q [...]
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
14/09/2026
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, [...]

Pages